With sales of the oral GLP-1 medicine rising quickly, executives reassured investors that Novo has secured production capacity to support continued growth.
Novo targets 10-fold jump in oral Wegovy manufacturing capacity by 2030 Read More »
While Vertex is laser-focused on an upcoming FDA decision for povetacicept in immunoglobulin A nephropathy, the APOL1 inhibitor inaxaplin has demonstrated potential “best-in-class” data in a different kidney disease.
Vertex opens up larger kidney disease opportunity with mid-stage readout Read More »
Viking Therapeutics’ VK2735 met Truist’s “best-case scenario,” with robust weight loss that was largely maintained when patients transitioned to less frequent dosing. Viking’s stock popped more than 30% on Tuesday.
Viking achieves ‘maintenance trifecta’ as GLP-/GIP dual agonist exceeds expectations Read More »
The new lawsuit, filed on behalf of five Medicaid enrollees and a swath of provider groups, says the CMS narrowed exemptions for those too sick to fulfill upcoming work requirements in the safety-net insurance program.
New lawsuit targets Medicaid work requirements’ medical frailty rules Read More »
With more than 25 companies debuting on the public markets, 2026 has recorded the highest number of biotech IPOs since 2021. Now, four companies—including Iambic Therapeutics and ADARx Pharmaceuticals—are looking to grow this total even further.
2026 IPO blitz continues with 4 new biotech filings Read More »
Despite a $2.8B settlement over BlueCard program disputes, five HCA-affiliated hospitals say the program still traps them in red tape.
Texas hospitals sue Independence Blue Cross over denied claims Read More »
With a trillion-dollar market cap and a wildly successful GLP-1 portfolio, Eli Lilly isn’t resting on its laurels. At the Psych Congress 2026, the company presented early-stage data that could support the potential of its next-gen GLP-1 and GIP receptor agonist to treat diseases far beyond obesity.
Envisagenics’ platform makes use of AI to screen and detect cancer-specific RNA alterations, which Boehringer Ingelheim wants to target through various precision treatment modalities, including multi-specific antibodies, antibody-drug conjugates and T cell engagers.
Boehringer Ingelheim bets up to $1B in AI-centered solid tumor collab with Envisagenics Read More »
The mid-stage readout is one link in a chain of catalysts that analysts were watching for this year from Roche’s metabolic pipeline, which features assets from the $2.7 billion acquisition of Carmot Therapeutics as well as partner Zealand Pharma.
Roche’s Carmot asset normalizes blood sugar, cuts weight in Phase 2 diabetes trial Read More »
Novo CEO Maziar Mike Doustdar disclosed an additional 4,000 staff departures, which a spokesperson told BioSpace are linked to attrition and other measures.
Novo’s workforce reduction climbs to 13,000 to fuel R&D work Read More »
